Golden Throat Holdings Group Co Ltd (HK:6896)
:6896
Top Page
Golden Throat Holdings Group Co Ltd
(6896)
Select Model
Select Model
Rating:75Outperform
Price Target:
HK$3.50
▲(14.01% Upside)
Action:ReiteratedDate:10/18/25
Golden Throat Holdings demonstrates strong financial performance with robust revenue growth and profitability, supported by a stable balance sheet. The valuation is attractive with a low P/E ratio and high dividend yield, making it appealing for value and income investors. However, technical indicators suggest mixed market momentum, which could pose short-term challenges.
Positive Factors
High profitability margins
Sustained high gross and operating margins indicate durable pricing power and efficient production for a branded OTC product. These margins create a structural buffer versus input cost shocks, enable reinvestment in brand and distribution, and support long-term cash generation and shareholder returns.
Negative Factors
Missing 2024 operating cash flow data
Lack of disclosed operating cash flow for 2024 limits assessment of cash conversion and the quality of reported earnings. Even with prior free cash flow growth, this opacity increases uncertainty about current cash-generation reliability and the company’s ability to fund operations, capex, or dividends sustainably.
Read all positive and negative factors
Positive Factors
Negative Factors
High profitability margins
Sustained high gross and operating margins indicate durable pricing power and efficient production for a branded OTC product. These margins create a structural buffer versus input cost shocks, enable reinvestment in brand and distribution, and support long-term cash generation and shareholder returns.
Read all positive factors
Golden Throat Holdings Group Co Ltd (6896) vs. iShares MSCI Hong Kong ETF (EWH)
Market Cap
HK$2.72B
Dividend Yield15.97%
Average Volume (3M)691.97K
Price to Earnings (P/E)8.8
Beta (1Y)0.20
Revenue Growth-2.70%
EPS Growth2.19%
CountryHK
Employees874
SectorHealthcare
Sector Strength45
IndustryDrug Manufacturers - Specialty & Generic
Share Statistics
EPS (TTM)0.25
Shares Outstanding739,302,000
10 Day Avg. Volume656,610
30 Day Avg. Volume691,973
Financial Highlights & Ratios
PEG Ratio0.27
Price to Book (P/B)1.53
Price to Sales (P/S)1.90
P/FCF Ratio5.51
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
EPS Forecast (FY)N/A
Revenue Forecast (FY)N/A
Golden Throat Holdings Group Co Ltd Business Overview & Revenue Model
Company Description
Golden Throat Holdings Group Company Limited, an investment holding company, manufactures and sells pharmaceutical, healthcare food, and other products in the People's Republic of China. It offers Golden Throat lozenges over-the-counter medicine t...
How the Company Makes Money
Golden Throat Holdings Group Co Ltd generates revenue through multiple streams, predominantly from the sale of its diverse product lines in the food and beverage sector. The company capitalizes on its strong brand recognition and distribution netw...
Golden Throat Holdings Group Co Ltd Financial Statement Overview
Summary
Income Statement
88
Very Positive
Balance Sheet
85
Very Positive
Cash Flow
70
Positive
| Breakdown | TTM | Dec 2024 | Dec 2023 | Dec 2022 | Dec 2021 | Dec 2020 |
|---|---|---|---|---|---|---|
Income Statement | ||||||
| Total Revenue | 979.71M | 1.19B | 961.38M | 992.01M | 820.54M | 646.94M |
| Gross Profit | 748.65M | 894.18M | 697.72M | 720.92M | 577.74M | 475.64M |
| EBITDA | 373.17M | 456.65M | 410.75M | 424.93M | 281.80M | 233.31M |
| Net Income | 268.11M | 318.63M | 250.16M | 281.22M | 187.64M | 154.05M |
Balance Sheet | ||||||
| Total Assets | 2.12B | 2.25B | 2.30B | 2.30B | 1.95B | 1.69B |
| Cash, Cash Equivalents and Short-Term Investments | 1.06B | 1.14B | 1.07B | 925.51M | 802.84M | 705.54M |
| Total Debt | 684.03M | 426.92M | 412.34M | 272.59M | 235.00M | 152.45M |
| Total Liabilities | 914.07M | 784.87M | 748.34M | 760.18M | 588.04M | 464.75M |
| Stockholders Equity | 1.21B | 1.47B | 1.55B | 1.54B | 1.37B | 1.22B |
Cash Flow | ||||||
| Free Cash Flow | 185.70M | 408.65M | 221.30M | 255.30M | 116.23M | 83.80M |
| Operating Cash Flow | 238.09M | 475.87M | 238.84M | 271.15M | 164.89M | 167.75M |
| Investing Cash Flow | -12.19M | -41.60M | -59.67M | 36.59M | -145.11M | -81.26M |
| Financing Cash Flow | -87.37M | -335.18M | -79.38M | -142.01M | -10.21M | 49.36M |
Golden Throat Holdings Group Co Ltd Technical Analysis
Positive
3.07
Price Trends
3.29
Positive
3.27
Positive
3.62
Positive
Market Momentum
0.13
Negative
67.57
Neutral
73.81
Neutral
Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For HK:6896, the sentiment is Positive. The current price of 3.07 is below the 20-day moving average (MA) of 3.48, below the 50-day MA of 3.29, and below the 200-day MA of 3.62, indicating a bullish trend. The MACD of 0.13 indicates Negative momentum. The RSI at 67.57 is Neutral, neither overbought nor oversold. The STOCH value of 73.81 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Positive sentiment for HK:6896.
Golden Throat Holdings Group Co Ltd Peers Comparison
UnderperformOutperform
Sector (51)
Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
|---|---|---|---|---|---|---|---|
75 Outperform | HK$2.72B | 8.85 | 20.05% | 15.97% | -2.70% | 2.19% | |
75 Outperform | HK$2.18B | 5.29 | 20.10% | 9.98% | 12.83% | 36.12% | |
73 Outperform | HK$7.37B | 6.31 | 11.90% | 5.80% | -20.64% | -25.39% | |
68 Neutral | HK$677.60M | 12.96 | 1.57% | 9.43% | -1.99% | -81.52% | |
66 Neutral | HK$1.74B | 7.90 | 6.34% | 5.16% | 2.89% | -68.83% | |
51 Neutral | $7.86B | -0.30 | -43.30% | 2.27% | 22.53% | -2.21% | |
42 Neutral | HK$163.16M | -4.22 | -30.35% | ― | -17.32% | 55.74% |
* Healthcare Sector Average
HK:6896
Golden Throat Holdings Group Co Ltd
3.68
0.04
1.10%
HK:1498
PuraPharm Corp. Ltd.
0.31
-0.20
-39.00%
HK:2161
JBM (Healthcare) Ltd.
2.65
1.13
74.34%
HK:2348
Dawnrays Pharmaceutical Holdings Ltd.
1.16
0.15
14.85%
HK:2877
China Shineway Pharmaceutical Group Limited
9.76
2.82
40.63%
HK:3737
Zhongzhi Pharmaceutical Holdings Limited
0.80
-0.04
-4.76%
Golden Throat Holdings Group Co Ltd Corporate Events
Golden Throat Tightens Nomination Committee Rules to Boost Governance and Board Diversity
Dec 24, 2025
Golden Throat Holdings Group Company Limited has updated the terms of reference for its Board Nomination Committee, originally adopted in 2015 and now revised as of 24 December 2025. The revised framework formalises the committee’s compositi...
Glossary
BuyA stock rated as a "Buy" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock is likely to deliver higher returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
HoldA stock rated as a "Hold" is expected to perform in line with the overall market or a specific benchmark. This rating indicates that the stock is neither particularly compelling nor unfavorable for investment. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
SellA stock rated as a "Sell" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock may deliver lower returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
Disclaimer
This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.